Pharmaceuticals

Follicular Lymphoma Treatment Market Surges Amidst Growing Prevalence Is Supporting Development Across The Follicular Lymphoma Treatment Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Follicular Lymphoma Treatment Market Change Between 2026 And 2030?

The follicular lymphoma treatment market has exhibited strong growth in recent years. It is projected to expand from $3.28 billion in 2025 to $3.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Historically, this market’s expansion can be ascribed to advancements in monoclonal antibodies, increased awareness regarding lymphoma, the growth of oncology research, the development of hospital infrastructure, and a rising incidence of non-hodgkin lymphoma.

The follicular lymphoma treatment market is predicted to experience significant expansion over the next few years. It is projected to reach $4.91 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth throughout the forecast period is fueled by advancements in targeted therapy, the incorporation of artificial intelligence into treatment planning, an increase in stem cell transplant procedures, the proliferation of oncology centers in emerging markets, and the introduction of biosimilars. Prominent trends anticipated for this period include personalized treatment protocols, the creation of innovative monoclonal antibodies, the adoption of combination therapy approaches, intensified early diagnosis and screening efforts, and the application of minimally invasive treatment techniques.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp

What Important Drivers Are Powering The Follicular Lymphoma Treatment Market Growth?

The follicular lymphoma treatment market is anticipated to expand due to the increasing prevalence of follicular lymphoma. Prevalence indicates the total count or percentage of individuals in a specific population diagnosed with follicular lymphoma at a given time or over a defined duration. This rise is attributed to an aging population, genetic predisposition, advancements in diagnostic methods, and enhanced awareness and screening efforts. Treating follicular lymphoma assists in lowering its prevalence by managing the disease across different stages and supporting its treatment and progression control. The growing incidence of follicular lymphoma is further fueling the expansion of its treatment market. For instance, in January 2023, the American Cancer Society, a US-based voluntary organization, reported that non-Hodgkin lymphoma, an indolent form of follicular lymphoma, stands as the most common cancer in the US, making up approximately 4% of all cancer cases. The American Cancer Society projects around 80,550 diagnoses of NHL (comprising 44,880 men and 35,670 women), encompassing both adults and children. Consequently, the increasing prevalence of follicular lymphoma is a key driver for the growth of the follicular lymphoma treatment market.

What Segment Categories Are Evaluated In The Follicular Lymphoma Treatment Market Study?

The follicular lymphoma treatment market covered in this report is segmented –

1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents

2) By Product Type: Tablets, Capsules, Injectables, Other Product Types

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab

2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors

3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy

5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant

6) By Alkylating Agents: Cyclophosphamide, Ifosfamide

What Trends Are Driving Changes In The Follicular Lymphoma Treatment Market?

Major companies in the follicular lymphoma treatment market are focusing on developing advanced solutions like bispecific antibodies to enhance durable remission and reduce the patient treatment burden. A bispecific antibody is an engineered molecule designed to simultaneously bind two different targets; for example, one arm binds a tumor antigen on B cells and the other engages T cells, thus redirecting the immune system to kill cancer cells more efficiently. For instance, in March 2025, Chugai Pharmaceutical, a Japan-based research-driven oncology company, launched LUNSUMIO, which features a CD20/CD3 bispecific antibody system. LUNSUMIO is approved as an intravenous infusion in 1 mg and 30 mg formulations. It is intended for patients with relapsed or refractory follicular lymphoma who have failed at least two prior standard therapies. The therapy is designed for fixed-duration treatment based on individual patient response, which can potentially reduce the long-term treatment burden. LUNSUMIO has demonstrated high complete response rates and holds the potential to deliver durable remission as a monotherapy.

Which Firms Are Competing In The Follicular Lymphoma Treatment Market?

Major companies operating in the follicular lymphoma treatment market are AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc.

Access The Complete Follicular Lymphoma Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Which Area Represents The Largest Portion Of The Follicular Lymphoma Treatment Market?

North America was the largest region in the follicular lymphoma treatment market in 2025. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Follicular Lymphoma Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp

Browse Through More Reports Similar to the Global Follicular Lymphoma Treatment Market 2026, By The Business Research Company

Follicular Lymphoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Emphysema Market Report 2026

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Diffuse Large B Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795